AURIS评分用于预测ICU中耳念珠菌定植患者念珠菌血症的开发与验证
该双中心回顾性队列研究在西班牙两家三级医院ICU中,对外部验证了原有预测模型并用弹性净回归优化,形成四变量AURIS评分。
要点
- AURIS评分含四个预测因子:全肠外营养、既往抗真菌治疗、多部位定植和尿路分离。
核心结论
- AURIS评分可用于耳念珠菌定植ICU患者的念珠菌血症风险分层,有助于识别低风险患者并减少不必要的经验性抗真菌治疗。
研究设计与样本
- 外部验证队列纳入216例耳念珠菌定植ICU患者,其中31例(14%)发生念珠菌血症。
- 将外部验证队列与原推导队列合并,获得422例双中心数据集,其中68例(16%)发生念珠菌血症。
- 采用弹性净回归优化模型,并通过bootstrap重采样(n=5000)进行内部验证。
主要发现
- 外部验证队列中216例耳念珠菌定植ICU患者有31例(14%)发生念珠菌血症。
- 合并双中心数据集422例患者中68例(16%)发生念珠菌血症。
关键数值与推荐
- AURIS评分包含全肠外营养、既往抗真菌治疗、多部位定植和尿路分离四个变量。
- 已创建图形列线图和基于积分的评分用于床旁风险评估。
临床怎么用
- 对ICU中耳念珠菌定植患者可使用AURIS评分进行念珠菌血症风险分层。
- 评分有助于识别低风险患者,从而减少不必要的经验性抗真菌治疗。
- 预测因子提示应关注多部位定植者、尿路定植、既往抗真菌暴露和全肠外营养患者。
局限性
- 研究为双中心回顾性队列,需在多样化的分支和流行病学环境中进一步验证后才能广泛实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Candidozyma auris is an emerging multidrug-resistant pathogen that frequently colonises hospitalised patients and can cause invasive disease. Traditional tools, such as the Candida score, perform poorly in this setting. We aimed to externally validate and refine a clinical prediction model for C auris candidaemia among colonised patients in the intensive care unit (ICU). METHODS: We performed a retrospective analysis of prospectively and systematically collected cohort data from ICUs in two tertiary-care hospitals in Valencia, Spain, to predict candidaemia among adult C auris-colonised patients during prolonged outbreaks (October, 2017, to March, 2020). A previously derived logistic regression-based prediction model was externally validated, then refined in a bicentric cohort using Elastic Net regression. Internal validation was performed by bootstrap resampling (n=5000). Model discrimination and calibration were assessed and compared with the Candida score. FINDINGS: In the external validation cohort, 216 C auris-colonised ICU patients were included, of whom 31 (14%) developed candidaemia. After pooling this cohort with the original derivation cohort, a bicentric dataset of 422 patients was obtained, with 68 (16%) candidaemia events. Four predictors were retained: total parenteral nutrition (TPN; p<0·0001), previous antifungal therapy (p=0·027), multifocal colonisation (p=0·0020), and urinary isolation (p=0·029). These formed a simplified four-variable model (AURIS score) with a validated area under the curve of 0·81, outperforming the Candida score (0·75; p=0·0003). A graphical nomogram and point-based score for bedside risk estimation was created. At a 28% threshold, sensitivity was 0·72, specificity 0·84, and negative predictive value 0·94. INTERPRETATION: The AURIS score provides a pragmatic tool for risk stratification among C auris-colonised ICU patients, with value in identifying those at low risk of candidaemia, reducing unnecessary empirical antifungal therapy. Its predictors highlight the risk in multi-colonised carriers, the relevance of urinary colonisation, the ecological advantage from previous antifungal exposure, and the strong association with TPN. Broader validation across diverse clades and epidemiological settings is warranted before widespread implementation. FUNDING: None. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.
引用
- Garcia-Bustos V, Puchades F, Alonso-Ecenarro F, et al. Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study. Lancet Infect Dis. 2026. PMID: 41720147. doi:10.1016/S1473-3099(26)00002-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。